Lyell Immunopharma
LYEL
LYEL
113 hedge funds and large institutions have $81.8M invested in Lyell Immunopharma in 2025 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 23 increasing their positions, 36 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
15% less capital invested
Capital invested by funds: $95.9M → $81.8M (-$14.1M)
33% less call options, than puts
Call options by funds: $2K | Put options by funds: $3K
36% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 36
Holders
113
Holding in Top 10
6
Calls
$2K
Puts
$3K
Top Buyers
| 1 | +$4.13M | |
| 2 | +$770K | |
| 3 | +$392K | |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$238K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$141K |
Top Sellers
| 1 | -$1.99M | |
| 2 | -$492K | |
| 3 | -$478K | |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$445K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$406K |
